The FDA, CDC, & Western States Scientific Safety Review Workgroup have approved the EAU for the new Pfizer and Moderna mRNA bivalent vaccines. These vaccines target the COVID-19 spike protein, which has rapidly mutated over the course of the pandemic. These vaccines target the original Wuhan spike protein (monovalent vaccines) and the Omicron BA.4 & BA.5 subvariants. BA .5 has proved very contagious and still accounts for over 88% of the infections in California. Though the numbers of COVID cases, hospitalizations, and deaths have slowly improved since the end of July, the rates are still substantial. On 9/8/22, a large 250-hospital network study of COVID-19 hospitalizations in the USA from January 2021-April 2022 was published in JAMA IM (https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2796235). They found the rate of hospitalization was 10.5 times greater for unvaccinated and 2.5 times higher for vaccinated, but not boosted. We anticipate an even greater benefit of the new bivalent vaccines which better target BA .5. This vaccine roll-out is well timed to combine with our efforts to provide the usual Flu vaccines before winter arrives. As of 9/10, over 50 million doses have been delivered to states for distribution.